Your shopping cart is currently empty

GPR120 Agonist 3 (GPR120-IN-1) is a selective agonist of Gpr120 ( logEC50: -7.62).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $31 | In Stock | In Stock | |
| 5 mg | $81 | In Stock | In Stock | |
| 10 mg | $147 | In Stock | In Stock | |
| 25 mg | $289 | In Stock | In Stock | |
| 50 mg | $413 | In Stock | In Stock | |
| 100 mg | $619 | In Stock | In Stock | |
| 200 mg | $877 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $89 | In Stock | In Stock |
| Description | GPR120 Agonist 3 (GPR120-IN-1) is a selective agonist of Gpr120 ( logEC50: -7.62). |
| Targets&IC50 | GPR120:−7.62 (logEC50) |
| In vitro | GPR120-IN-1 causes a concentration-dependent response to recruiting β-arrestin-2 in both human and mouse Gpr120 expressing cells(EC50s: ~0.35 μM). GPR120-IN-1 produces concentration-dependent increases in IP3 production from both human and mouse Gpr120 expressing cells. GPR120-IN-1 strongly and comparably inhibits LPS-induced phosphorylation of Ikkβ, Tak1, and Jnk and blocked IκB degradation. |
| In vivo | GPR120-IN-1 treatment has beneficial effects on hepatic lipid metabolism. It causes decreased liver triglycerides, decreased hepatic steatosis, and DAGs, as well as decreased saturated free fatty acid content. GPR120-IN-1 causes improved insulin sensitivity with increased glucose infusion rates. It also enhanced the insulin stimulated-glucose disposal rate. Only in WT mice, along with a marked increase in the ability of insulin to suppress hepatic glucose production. |
| Synonyms | GPR120-IN-1 |
| Molecular Weight | 405.84 |
| Formula | C19H23ClF3NO3 |
| Cas No. | 1599477-75-4 |
| Smiles | OC(=O)CC1CCC2(CC1)CCN(CC2)c1cc(OC(F)(F)F)ccc1Cl |
| Relative Density. | 1.35 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (123.2 mM), Sonication is recommended. H2O: < 0.1 mg/mL (insoluble), Sonication and heating to 60℃ are recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.93 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.